No Data
No Data
Outlook Therapeutics Price Target Cut to $24.00/Share From $33.00 by Ascendiant Capital
Outlook Therapeutics Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Outlook Therapeutics Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Cuts Target Price to $3